109 related articles for article (PubMed ID: 10075159)
1. Immunization with a LEAPS heteroconjugate containing a CTL epitope and a peptide from beta-2-microglobulin elicits a protective and DTH response to herpes simplex virus type 1.
Rosenthal KS; Mao H; Horne WI; Wright C; Zimmerman D
Vaccine; 1999 Feb; 17(6):535-42. PubMed ID: 10075159
[TBL] [Abstract][Full Text] [Related]
2. A L.E.A.P.S. heteroconjugate vaccine containing a T cell epitope from HSV-1 glycoprotein D elicits Th1 responses and protection.
Goel N; Rong Q; Zimmerman D; Rosenthal KS
Vaccine; 2003 Oct; 21(27-30):4410-20. PubMed ID: 14505924
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity of herpes simplex virus type 1 mutants containing deletions in one or more alpha-genes: ICP4, ICP27, ICP22, and ICP0.
Brehm M; Samaniego LA; Bonneau RH; DeLuca NA; Tevethia SS
Virology; 1999 Apr; 256(2):258-69. PubMed ID: 10191191
[TBL] [Abstract][Full Text] [Related]
4. J-LEAPS vaccines initiate murine Th1 responses by activating dendritic cells.
Taylor PR; Koski GK; Paustian CC; Bailey E; Cohen PA; Moore FB; Zimmerman DH; Rosenthal KS
Vaccine; 2010 Aug; 28(34):5533-42. PubMed ID: 20600501
[TBL] [Abstract][Full Text] [Related]
5. Protective immunity against herpes simplex virus (HSV) type 1 following oral administration of recombinant Salmonella typhimurium vaccine strains expressing HSV antigens.
Karem KL; Bowen J; Kuklin N; Rouse BT
J Gen Virol; 1997 Feb; 78 ( Pt 2)():427-34. PubMed ID: 9018066
[TBL] [Abstract][Full Text] [Related]
6. Herpes simplex virus type 1-specific cytotoxic T lymphocytes recognize immediate-early protein ICP27.
Banks TA; Allen EM; Dasgupta S; Sandri-Goldin R; Rouse BT
J Virol; 1991 Jun; 65(6):3185-91. PubMed ID: 1709698
[TBL] [Abstract][Full Text] [Related]
7. Ligand epitope antigen presentation system vaccines against herpes simplex virus.
Goel N; Zimmerman DH; Rosenthal KS
Front Biosci; 2005 Jan; 10():966-74. PubMed ID: 15569635
[TBL] [Abstract][Full Text] [Related]
8. Induction of cross clade reactive specific antibodies in mice by conjugates of HGP-30 (peptide analog of HIV-1(SF2) p17) and peptide segments of human beta-2-microglobulin or MHC II beta chain.
Zimmerman DH; Lloyd JP; Heisey D; Winship MD; Siwek M; Talor E; Sarin PS
Vaccine; 2001 Sep; 19(32):4750-9. PubMed ID: 11535326
[TBL] [Abstract][Full Text] [Related]
9. Creating CTL targets with epitope-linked beta 2-microglobulin constructs.
Uger RA; Barber BH
J Immunol; 1998 Feb; 160(4):1598-605. PubMed ID: 9469415
[TBL] [Abstract][Full Text] [Related]
10. Influenza, but not HIV-specific CTL epitopes, elicits delayed-type hypersensitivity (DTH) reactions in HIV-infected patients.
Ruiz-Riol M; Mothe B; Gandhi RT; Bhardwaj N; Scadden DT; Sanchez-Merino V; Brander C
Eur J Immunol; 2013 Jun; 43(6):1545-54. PubMed ID: 23504637
[TBL] [Abstract][Full Text] [Related]
11. Protective immunity against ocular herpes infection and disease induced by highly immunogenic self-adjuvanting glycoprotein D lipopeptide vaccines.
Bettahi I; Nesburn AB; Yoon S; Zhang X; Mohebbi A; Sue V; Vanderberg A; Wechsler SL; BenMohamed L
Invest Ophthalmol Vis Sci; 2007 Oct; 48(10):4643-53. PubMed ID: 17898288
[TBL] [Abstract][Full Text] [Related]
12. Induction and persistence of a cytotoxic T lymphocyte (CTL) response against a herpes simplex virus-specific CTL epitope expressed in a cellular protein.
Fu TM; Bonneau RH; Epler M; Tevethia MJ; Alam S; Verner K; Tevethia SS
Virology; 1996 Aug; 222(1):269-74. PubMed ID: 8806508
[TBL] [Abstract][Full Text] [Related]
13. Induction of protective CTL responses against the Plasmodium yoelii circumsporozoite protein by immunization with peptides.
Franke ED; Corradin G; Hoffman SL
J Immunol; 1997 Oct; 159(7):3424-33. PubMed ID: 9317141
[TBL] [Abstract][Full Text] [Related]
14. Full length antigen priming enhances the CTL epitope-based DNA vaccine efficacy.
Pouriayevali MH; Bamdad T; Parsania M; Sari RD
Cell Immunol; 2011; 268(1):4-8. PubMed ID: 21324438
[TBL] [Abstract][Full Text] [Related]
15. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells.
Feltkamp MC; Smits HL; Vierboom MP; Minnaar RP; de Jongh BM; Drijfhout JW; ter Schegget J; Melief CJ; Kast WM
Eur J Immunol; 1993 Sep; 23(9):2242-9. PubMed ID: 7690326
[TBL] [Abstract][Full Text] [Related]
16. In vivo priming and activation of memory cytotoxic T-lymphocytes (CTL) by a chimeric simian virus 40 T antigen expressing an eight amino acid residue herpes simplex virus gB CTL epitope.
Bonneau RH; Fu TM; Tevethia SS
Virology; 1993 Dec; 197(2):782-7. PubMed ID: 7504370
[TBL] [Abstract][Full Text] [Related]
17. Use of a lentiviral vector encoding a HCMV-chimeric IE1-pp65 protein for epitope identification in HLA-Transgenic mice and for ex vivo stimulation and expansion of CD8(+) cytotoxic T cells from human peripheral blood cells.
Rohrlich PS; Cardinaud S; Lulè J; Montero-Julian FA; Prodhomme V; Firat H; Davignon JL; Perret E; Monseaux S; Necker A; Michelson S; Lemonnier FA; Charneau P; Davrinche C
Hum Immunol; 2004 May; 65(5):514-22. PubMed ID: 15172452
[TBL] [Abstract][Full Text] [Related]
18. Identification of novel immunodominant CD4+ Th1-type T-cell peptide epitopes from herpes simplex virus glycoprotein D that confer protective immunity.
BenMohamed L; Bertrand G; McNamara CD; Gras-Masse H; Hammer J; Wechsler SL; Nesburn AB
J Virol; 2003 Sep; 77(17):9463-73. PubMed ID: 12915561
[TBL] [Abstract][Full Text] [Related]
19. Effect of natural sequence variation at the H-2Ld-restricted CD8+ T cell epitope of the murine cytomegalovirus ie1-encoded pp89 on T cell recognition.
Lyons PA; Allan JE; Carrello C; Shellam GR; Scalzo AA
J Gen Virol; 1996 Oct; 77 ( Pt 10)():2615-23. PubMed ID: 8887498
[TBL] [Abstract][Full Text] [Related]
20. Vaccination and protection from a lethal viral infection: identification, incorporation, and use of a cytotoxic T lymphocyte glycoprotein epitope.
Klavinskis LS; Whitton JL; Joly E; Oldstone MB
Virology; 1990 Oct; 178(2):393-400. PubMed ID: 1699348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
